{
    "2020-06-10": [
        [
            {
                "time": "2020-03-15",
                "original_text": "Fauci: Sped-up production on coronavirus vaccine risky and costly — but worth it",
                "features": {
                    "keywords": [
                        "vaccine",
                        "coronavirus",
                        "risky",
                        "costly",
                        "worth"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-11-10",
                "original_text": "Buy Pfizer (PFE) Stock for Massive Upside Ahead",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock",
                        "Massive",
                        "Upside"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-05",
                "original_text": "Pfizer’s Abrocitinib Candidate Shows Positive Results In Kids With Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Abrocitinib",
                        "Positive",
                        "Results",
                        "Atopic",
                        "Dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-10",
                "original_text": "Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "JADE TEEN",
                        "Trial",
                        "Abrocitinib",
                        "Positive",
                        "Top-Line",
                        "Results",
                        "Adolescents",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}